Clinical Phenotypes in Pericarditis: IL-1RA Antibodies and suPAR Levels (PERIPLO)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05925790 |
Recruitment Status :
Not yet recruiting
First Posted : June 29, 2023
Last Update Posted : June 29, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Pericarditis | Diagnostic Test: IL1RA Antibody Assay Diagnostic Test: suPAR Testing |
Recurrent pericarditis (RP) is a complex challenging condition, which significantly impacts patients' quality of life, both from the physical and emotional point of view, and can lead to dangerous complications such as cardiac tamponade and constrictive pericarditis. Moreover, patients experiencing several recurrences also tend to need substantial healthcare resources without necessarily experiencing clinical improvement. Understanding more into details the pathophysiology underlying RP is certainly of pivotal importance for optimizing workup strategies and treatment protocols. It is now recognized that pericarditis stems from a bidirectional cross-talk between environmental triggers and the innate and adaptive immune systems in a genetically susceptible host, with a central role of the pro-inflammatory agonistic molecule IL-1 (IL-1α and IL-1β) and the so-called inflammasome.
Neutralizing autoantibodies have been identified targeting the endogenous interleukin-1 receptor antagonist (IL-1RA) in conditions characterized by severe systemic inflammation such as myocarditis after Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination, Coronavirus Disease (COVID-19) and Multisystem Inflammatory Syndrome (MIS-C). Therefore, it is possible to hypothesize that testing patients with RP for these antibodies might add significant insights into the knowledge of the pathophysiology of this condition. This may help uncover different underlying mechanisms with similar clinical presentations. New mechanisms involving hyperphosphorylation of IL-1RA precede peripheral immune tolerance breakdown, which may also contribute to certain pericarditis phenotypes.
Therefore, it is possible to hypothesize that IL-1RA antibody testing could provide important information to better profile RP patients with an inflammatory phenotype (as indicated by common biochemical markers like CRP) and those with a complicated clinical course. These patients often exhibit marked activation of the IL-1 signaling pathway, and IL-1RA antibody testing may help uncover underlying mechanisms and improve their characterization. Given the negative correlation between neutralizing antibodies against IL-1RA (and low circulating levels of IL-1RA) and markers of cardiac damage and inflammation, testing these antibodies in RP might be of value. High titers of IL-1RA antibodies in RP may indicate uncontrolled activation of the IL-1 pathway, shedding light on why some patients experience recurrences when tapering treatment with the naturally occurring IL-1 receptor antagonist, anakinra. Testing these IL-1RA antibodies in other types of pericarditis could also help explore their correlation with clinical phenotypes, including presentation, clinical course, and response to treatment strategies. Key exclusion criteria include pericarditis secondary to specific etiologies (except post-cardiac injury), history of immunosuppression, and any clinical conditions that may influence the results.
Additionally, suPAR testing can complementarily highlight chronic low-grade inflammation, which may underlie certain pericarditis cases that do not exhibit an overt "inflammatory phenotype" (e.g., normal CRP) but are challenging to manage.
Longitudinal testing of patients during acute episodes and intercritical phases is planned if feasible.
In both IL-1RA antibody and suPAR testing, this study aims to provide more accurate markers compared to commonly used markers for the "inflammatory phenotype" and potentially uncover unknown pathophysiological mechanisms. Currently, there is a lack of literature on this topic.
The results of this study may provide a rationale for the selective use of anakinra in specific clinical scenarios and/or guide the evaluation of its dosing with an individualized approach.
Study Type : | Observational |
Estimated Enrollment : | 146 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Observational Study on Anti-interleukin-1 Receptor Antagonist Antibodies and Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Pericarditis: PERIPLO (PERicarditis: IL-1 RA Antibodies and suPAR Levels Observational) Study |
Estimated Study Start Date : | July 1, 2023 |
Estimated Primary Completion Date : | July 1, 2025 |
Estimated Study Completion Date : | December 20, 2025 |
Group/Cohort | Intervention/treatment |
---|---|
Inflammatory phenotype
Patients with the inflammatory phenotype of recurrent pericarditis exhibit signs indicating the presence of an inflammatory process during a recurrence. These signs may include one or more of the following:
|
Diagnostic Test: IL1RA Antibody Assay
-The measurement of anti-interleukin-1 receptor antagonist (IL1RA) antibodies will be performed using the ELISA (Enzyme-Linked Immunosorbent Assay) method,as previously described [Thurner, L., et al., IL-1RA Antibodies in Myocarditis after SARS-CoV-2 Vaccination. N Engl J Med, 2022. 387(16): p. 1524-1527]. Diagnostic Test: suPAR Testing -The quantitative determination of soluble urokinase plasminogen activator receptor (suPAR) levels in blood will be conducted using the commercially available "CHORUS suPAR Extended" kit (cod. 81414, DIESSE Diagnostica Senese S.p.A., Siena, Italy), based on the principle of the sandwich ELISA method. |
Non-inflammatory phenotype
Patients with the non-inflammatory phenotype of recurrent pericarditis do not exhibit any of the signs typically associated with an active inflammatory process during a recurrence. These patients present without:
|
Diagnostic Test: IL1RA Antibody Assay
-The measurement of anti-interleukin-1 receptor antagonist (IL1RA) antibodies will be performed using the ELISA (Enzyme-Linked Immunosorbent Assay) method,as previously described [Thurner, L., et al., IL-1RA Antibodies in Myocarditis after SARS-CoV-2 Vaccination. N Engl J Med, 2022. 387(16): p. 1524-1527]. Diagnostic Test: suPAR Testing -The quantitative determination of soluble urokinase plasminogen activator receptor (suPAR) levels in blood will be conducted using the commercially available "CHORUS suPAR Extended" kit (cod. 81414, DIESSE Diagnostica Senese S.p.A., Siena, Italy), based on the principle of the sandwich ELISA method. |
- Assessment of IL-1RA antibodies across pericarditis phenotypes [ Time Frame: 24 months ]
- Levels of anti-IL-1RA antibodies in different phenotypes of pericarditis.
- Levels of anti-IL-1RA antibodies during acute episodes and intercritical phases.
- Assessment of suPAR levels across pericarditis phenotypes [ Time Frame: 24 months ]
- Levels of suPAR in acute and recurrent pericarditis with normal C-reactive protein (CRP).
- Levels of suPAR during acute episodes and intercritical phases.
- Correlation of Time to Recurrence and Disease Activity with Anti-IL-1RA Antibodies in Pericarditis [ Time Frame: 24 months ]
- Correlate the time to recurrence with the levels of anti-IL-1RA antibodies.
- Correlate overall disease activity indices with the levels of anti-IL-1RA antibodies.
- Correlation of Time to Recurrence and Disease Activity with suPAR Levels in Pericarditis [ Time Frame: 24 months ]
- Correlate the time to recurrence with the levels of suPAR.
- Correlate overall disease activity indices with the levels of suPAR.
Biospecimen Retention: Samples Without DNA
Blood samples will be withdrawn to test:
- IL-1RA Antibodies;
- suPAR levels;
- biochemical tests used in routine clinical practice, including complete blood count, biochemistry panel (C-reactive protein, urea, creatinine, sodium, potassium, chloride, calcium, magnesium, total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, gamma-glutamyl transferase (gamma-GT), lactate dehydrogenase (LDH), creatine phosphokinase (CPK), albumin, serum iron, transferrin, ferritin, triglycerides, cholesterol + HDL), and coagulation parameters (prothrombin time - PT, activated partial thromboplastin Time - aPTT, fibrinogen, D-dimer).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 90 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Written informed consent from patients aged ≥ 18 years before any evaluation is performed.
- Written informed consent from parents or legal guardian and assent from minors aged under 18 years before any evaluation is performed.
- Recurrent acute pericarditis during the acute phase of the disease. The diagnosis of pericarditis is based on the presence of at least two of the following criteria: typical pericarditic chest pain (acute and pleuritic, worsened by positional changes or breathing), pericardial friction rub, diffuse ST segment elevation or PR depressions not previously reported, and pericardial effusion.
- Post-cardiac injury pericarditis (e.g., post-cardiac surgery) that is new or worsening. Recurrence is diagnosed based on the same criteria.
In all patients, the previous history of CRP values should be known to distinguish individuals with inflammatory forms (characterized by significantly elevated CRP values in the clinical history) from those with pericarditis and normal or near-normal CRP levels (clinical history of normal or at most less than 2 times the normal value).
The acute phase of the disease is defined as follows: for pericarditis forms with elevated CRP, the presence of a CRP that is at least double the normal value of the test. For forms with normal CRP, it is based on clinical judgment, as there are no other recognized and validated criteria.
Exclusion Criteria:
- Specific etiologies, including tuberculosis, neoplastic or purulent etiologies, post-cardiac injury syndromes, and autoimmune rheumatic diseases.
- Subjects under 18 years of age.
- Pregnant or lactating women.
- History of immunosuppression, including a positive result on HIV screening tests (ELISA and Western blot).
- Positive QuantiFERON test (QFT-Tuberculosis G In-Tube) or positive Purified Protein Derivative (PPD) test after the initial clinical evaluation.
- History of other significant medical conditions that, according to the investigator, could compromise the outcome or interpretation of the results (e.g., systemic diseases that are not directly the cause of pericarditis but may cause a state of chronic inflammation).
- Use of any medication that the investigator believes could alter the result of the tests to be performed (except those used for the treatment of pericarditis).
Throughout the study, patients will continue to receive the most appropriate therapies for their clinical condition, following current guidelines and good clinical practice, without the participation in the study prejudicing or influencing the choice of therapeutic strategies to be employed.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05925790
Contact: Maddalena A Wu | +393392883379 | maddalena.wu@unimi.it |
Germany | |
Saarland University | |
Homburg, Germany | |
Contact: Lorenz Thurner | |
Principal Investigator: Lorenz Thurner | |
Sub-Investigator: Natalie Fadle | |
Sub-Investigator: Evi Regitz | |
University Children's Hospital Muenster | |
Muenster, Germany | |
Contact: Christoph Kessel | |
Principal Investigator: Christoph Kessel | |
University Hospital Tübingen | |
Tübingen, Germany | |
Contact: Karin Klingel | |
Principal Investigator: Karin Klingel | |
Italy | |
A.O.U. Careggi | |
Florence, Italy | |
Contact: Giacomo Emmi | |
Principal Investigator: Giacomo Emmi | |
Luigi Sacco Hospital - ASST Fatebenefratelli Sacco | |
Milan, Italy, 20157 | |
Fatebenefratelli Hospital - ASST Fatebenefratelli Sacco | |
Milan, Italy | |
Contact: Antonio Brucato | |
Principal Investigator: Antonio Brucato | |
Ospedale Galeazzi Sant'Ambrogio - IRCCS, Poliambulatorio Cardiovascolare Cardiologia Universitaria | |
Milan, Italy | |
Contact: Edoardo Conte | |
Principal Investigator: Edoardo Conte | |
Policlinico di Milano Ospedale Maggiore, Fondazione IRCCS Ca' Granda | |
Milan, Italy | |
Contact: Ferruccio Ceriotti | |
Principal Investigator: Ferruccio Ceriotti | |
Sub-Investigator: Matteo Vidali | |
Ospedale Santa Maria della Misericordia dell'ASU-FC | |
Udine, Italy | |
Contact: Massimo Imazio | |
Principal Investigator: Massimo Imazio |
Principal Investigator: | Maddalena A Wu | ASST Fatebenefratelli Sacco | |
Study Director: | Antonio L Brucato | Fatebenefratelli Hospital |
Responsible Party: | Maddalena Alessandra Wu, MD, ASST Fatebenefratelli Sacco |
ClinicalTrials.gov Identifier: | NCT05925790 |
Other Study ID Numbers: |
2023/ST/094 |
First Posted: | June 29, 2023 Key Record Dates |
Last Update Posted: | June 29, 2023 |
Last Verified: | June 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Pericarditis Anti-interleukin-1 receptor antagonist antibodies Soluble urokinase plasminogen activator receptor Pericarditis phenotypes |
Pericarditis Heart Diseases Cardiovascular Diseases |
Antibodies Immunologic Factors Physiological Effects of Drugs |